JP2005519059A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005519059A5 JP2005519059A5 JP2003557592A JP2003557592A JP2005519059A5 JP 2005519059 A5 JP2005519059 A5 JP 2005519059A5 JP 2003557592 A JP2003557592 A JP 2003557592A JP 2003557592 A JP2003557592 A JP 2003557592A JP 2005519059 A5 JP2005519059 A5 JP 2005519059A5
- Authority
- JP
- Japan
- Prior art keywords
- gly
- ala
- glu
- arg
- glp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 6
- MFMDKJIPHSWSBM-GUBZILKMSA-N Ala-Lys-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O MFMDKJIPHSWSBM-GUBZILKMSA-N 0.000 description 4
- CCQOOWAONKGYKQ-BYPYZUCNSA-N Gly-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)CN CCQOOWAONKGYKQ-BYPYZUCNSA-N 0.000 description 4
- LLWQVJNHMYBLLK-CDMKHQONSA-N Gly-Thr-Phe Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LLWQVJNHMYBLLK-CDMKHQONSA-N 0.000 description 4
- AFPFGFUGETYOSY-HGNGGELXSA-N His-Ala-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AFPFGFUGETYOSY-HGNGGELXSA-N 0.000 description 4
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 4
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 4
- VZFPYFRVHMSSNA-JURCDPSOSA-N Phe-Ile-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=CC=C1 VZFPYFRVHMSSNA-JURCDPSOSA-N 0.000 description 4
- IVDFVBVIVLJJHR-LKXGYXEUSA-N Thr-Ser-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O IVDFVBVIVLJJHR-LKXGYXEUSA-N 0.000 description 4
- WMBFONUKQXGLMU-WDSOQIARSA-N Trp-Leu-Val Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N WMBFONUKQXGLMU-WDSOQIARSA-N 0.000 description 4
- KSCVLGXNQXKUAR-JYJNAYRXSA-N Tyr-Leu-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O KSCVLGXNQXKUAR-JYJNAYRXSA-N 0.000 description 4
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 4
- 108010006664 gamma-glutamyl-glycyl-glycine Proteins 0.000 description 4
- 108010073969 valyllysine Proteins 0.000 description 4
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 3
- RXVOMIADLXPJGW-GUBZILKMSA-N His-Asp-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O RXVOMIADLXPJGW-GUBZILKMSA-N 0.000 description 2
- HOYQLNNGMHXZDW-KKUMJFAQSA-N Phe-Glu-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O HOYQLNNGMHXZDW-KKUMJFAQSA-N 0.000 description 2
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- UKVFVQPAANCXIL-FJVFSOETSA-N glp-1 (1-37) amide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 UKVFVQPAANCXIL-FJVFSOETSA-N 0.000 description 1
- 108010063245 glucagon-like peptide 1 (7-36)amide Proteins 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0200507.2 | 2002-01-10 | ||
| GBGB0200507.2A GB0200507D0 (en) | 2002-01-10 | 2002-01-10 | Appetite suppression |
| US39210902P | 2002-06-28 | 2002-06-28 | |
| US60/392,109 | 2002-06-28 | ||
| USPCT/US02/31944 | 2002-09-24 | ||
| PCT/US2002/031944 WO2003026591A2 (en) | 2001-09-24 | 2002-09-24 | Modification of feeding behavior |
| PCT/GB2003/000062 WO2003057235A2 (en) | 2002-01-10 | 2003-01-10 | Modification of feeding behavior |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009193064A Division JP5226628B2 (ja) | 2002-01-10 | 2009-08-24 | 摂食行動の修正 |
| JP2010275256A Division JP2011052018A (ja) | 2002-01-10 | 2010-12-10 | 摂食行動の修正 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005519059A JP2005519059A (ja) | 2005-06-30 |
| JP2005519059A5 true JP2005519059A5 (cg-RX-API-DMAC7.html) | 2006-03-02 |
| JP4733922B2 JP4733922B2 (ja) | 2011-07-27 |
Family
ID=32992571
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003557592A Expired - Fee Related JP4733922B2 (ja) | 2002-01-10 | 2003-01-10 | 摂食行動の修正 |
| JP2009193064A Expired - Fee Related JP5226628B2 (ja) | 2002-01-10 | 2009-08-24 | 摂食行動の修正 |
| JP2010275256A Pending JP2011052018A (ja) | 2002-01-10 | 2010-12-10 | 摂食行動の修正 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009193064A Expired - Fee Related JP5226628B2 (ja) | 2002-01-10 | 2009-08-24 | 摂食行動の修正 |
| JP2010275256A Pending JP2011052018A (ja) | 2002-01-10 | 2010-12-10 | 摂食行動の修正 |
Country Status (5)
| Country | Link |
|---|---|
| EP (2) | EP2329839B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP4733922B2 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2003201998C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2472882A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003057235A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| US20050272652A1 (en) | 1999-03-29 | 2005-12-08 | Gault Victor A | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
| US8273713B2 (en) | 2000-12-14 | 2012-09-25 | Amylin Pharmaceuticals, Llc | Methods of treating obesity using PYY[3-36] |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| ATE419863T1 (de) | 2001-09-24 | 2009-01-15 | Imp Innovations Ltd | Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| BR0316685A (pt) | 2002-12-17 | 2005-11-01 | Nastech Pharm Co | Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade |
| US7186692B2 (en) | 2002-12-17 | 2007-03-06 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity |
| US7229966B2 (en) | 2002-12-17 | 2007-06-12 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity |
| WO2004089279A2 (en) * | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd. | Long-acting derivatives of pyy agonists |
| WO2005053726A1 (en) * | 2003-11-25 | 2005-06-16 | Bayer Pharmaceuticals Corporation | Selective neuropeptide y2 receptor agonists |
| EP2298337B1 (en) | 2003-12-09 | 2017-02-22 | Novo Nordisk A/S | Regulation of food preference using GLP-1 agonists |
| EP1718665B1 (en) | 2004-02-11 | 2013-04-10 | Amylin Pharmaceuticals, LLC | Hybrid polypeptides with selectable properties |
| US8076288B2 (en) | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
| EP2335715A3 (en) | 2004-02-11 | 2013-12-18 | Amylin Pharmaceuticals, LLC | Pancreatic polypeptide family motifs and polypeptides comprising the same |
| EP1737884B1 (en) | 2004-03-19 | 2016-10-19 | The University Of Queensland | Alpha helical mimics, their uses and methods for their production |
| EP1727912A2 (en) * | 2004-03-24 | 2006-12-06 | Integragen | Human obesity susceptibility genes encoding peptide hormones and uses thereof |
| WO2005110457A2 (en) * | 2004-05-18 | 2005-11-24 | Aditech Pharma Ab | Treatment of eating disorders and induction of lipolysis |
| EP1758575A1 (en) | 2004-06-11 | 2007-03-07 | Novo Nordisk A/S | Counteracting drug-induced obesity using glp-1 agonists |
| WO2006042242A2 (en) | 2004-10-08 | 2006-04-20 | Amylin Pharmaceuticals, Inc. | Amylin family polypeptide- 6 (afp- 6) analogs and methods of making and using them |
| WO2007055728A1 (en) * | 2005-11-01 | 2007-05-18 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
| ATE427759T1 (de) * | 2004-11-01 | 2009-04-15 | Amylin Pharmaceuticals Inc | Behandlung von fettsucht und verbundenen erkrankungen |
| US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| SG157423A1 (en) * | 2004-12-02 | 2009-12-29 | Domantis Ltd | Bispecific domain antibodies targeting serum albumin and glp-1 or pyy |
| AU2005316524B2 (en) | 2004-12-13 | 2012-01-12 | Amylin Pharmaceuticals, Llc | Pancreatic Polypeptide Family motifs, polypeptides and methods comprising the same |
| US8871712B2 (en) | 2005-01-14 | 2014-10-28 | Camurus Ab | Somatostatin analogue formulations |
| US8920782B2 (en) | 2005-01-14 | 2014-12-30 | Camurus Ab | Topical bioadhesive formulations |
| US9649382B2 (en) | 2005-01-14 | 2017-05-16 | Camurus Ab | Topical bioadhesive formulations |
| AU2005325510B2 (en) | 2005-01-21 | 2009-07-02 | Camurus Ab | Pharmaceutical lipid compositions |
| US8263545B2 (en) | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
| EP1853627A2 (en) | 2005-02-11 | 2007-11-14 | Amylin Pharmaceuticals, Inc. | Gip analog and hybrid polypeptides with selectable properties |
| GB0504857D0 (en) * | 2005-03-09 | 2005-04-13 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| ES2399645T3 (es) * | 2005-06-06 | 2013-04-02 | Camurus Ab | Formulaciones de análogos de GLP-1 |
| EP1922336B1 (en) | 2005-08-11 | 2012-11-21 | Amylin Pharmaceuticals, LLC | Hybrid polypeptides with selectable properties |
| BRPI0614649A2 (pt) | 2005-08-11 | 2011-04-12 | Amylin Pharmaceuticals Inc | polipeptìdeos hìbridos com propriedades selecionáveis |
| CA2624030A1 (en) | 2005-09-29 | 2007-04-12 | Tianying Jian | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| KR20080059233A (ko) | 2005-10-21 | 2008-06-26 | 노파르티스 아게 | 레닌 억제제, 및 항이상지질혈증제 및/또는 항비만제의조합물 |
| WO2007055743A2 (en) * | 2005-11-01 | 2007-05-18 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| NZ600394A (en) | 2006-05-04 | 2014-04-30 | Boehringer Ingelheim Int | Polymorphs of a dpp-iv enzyme inhibitor |
| US8497240B2 (en) | 2006-08-17 | 2013-07-30 | Amylin Pharmaceuticals, Llc | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
| CA2664113C (en) | 2006-09-22 | 2013-05-28 | Merck & Co., Inc. | Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer |
| TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| EP2145884B1 (en) | 2007-04-02 | 2014-08-06 | Msd K.K. | Indoledione derivative |
| ES2559319T3 (es) | 2007-06-04 | 2016-02-11 | Synergy Pharmaceuticals Inc. | Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| US8034782B2 (en) | 2008-07-16 | 2011-10-11 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| GB0711656D0 (en) | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
| GB0716385D0 (en) | 2007-08-22 | 2007-10-03 | Camurus Ab | Formulations |
| AR071175A1 (es) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
| EP2328910B1 (en) | 2008-06-04 | 2014-08-06 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| GB0815435D0 (en) | 2008-08-22 | 2008-10-01 | Camurus Ab | Formulations |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| WO2010053830A1 (en) * | 2008-11-05 | 2010-05-14 | Merck Sharp & Dohme Corp. | Mechanism of neuromedin u action and uses thereof |
| WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| US20120058116A1 (en) * | 2009-04-24 | 2012-03-08 | Andrew Beaton | Fgfr1c antibody combinations |
| CN102753161A (zh) | 2009-11-27 | 2012-10-24 | 贝林格尔.英格海姆国际有限公司 | 基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗 |
| US9018348B2 (en) | 2010-04-27 | 2015-04-28 | Agency For Science, Technology And Research | eIF4E binding peptides |
| CN107961377B (zh) | 2010-05-05 | 2022-11-22 | 勃林格殷格翰国际有限公司 | 组合疗法 |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| SG189444A1 (en) * | 2010-10-19 | 2013-05-31 | Elcelyx Therapeutics Inc | Chemosensory receptor ligand-based therapies |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| GB201101459D0 (en) | 2011-01-27 | 2011-03-16 | Imp Innovations Ltd | Novel compounds and thier effects on fedding behaviour |
| WO2013004983A1 (en) | 2011-07-04 | 2013-01-10 | Imperial Innovations Limited | Novel compounds and their effects on feeding behaviour |
| US20130172244A1 (en) * | 2011-12-29 | 2013-07-04 | Thomas Klein | Subcutaneous therapeutic use of dpp-4 inhibitor |
| US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
| MX350964B (es) | 2012-05-25 | 2017-09-27 | Camurus Ab | Formulaciones de agonistas del receptor de somatostatina. |
| WO2014049610A2 (en) | 2012-09-26 | 2014-04-03 | Cadila Healthcare Limited | Peptides as gip, glp-1 and glucagon receptors triple-agonist |
| AU2014235215A1 (en) | 2013-03-15 | 2015-10-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| BR112015030326A2 (pt) | 2013-06-05 | 2017-08-29 | Synergy Pharmaceuticals Inc | Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos |
| ES2901114T3 (es) | 2014-08-29 | 2022-03-21 | Tes Pharma S R L | Inhibidores de ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa |
| CA3022202A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
| MX2019004321A (es) | 2016-10-14 | 2019-06-12 | Tes Pharma S R L | Inhibidores de la acido alfa-amino-beta-carboximuconico semialdehido descarboxilasa. |
| EP3625247A4 (en) * | 2017-05-16 | 2021-03-24 | The University of Chicago | COMPOSITIONS AND METHODS FOR TREATMENT AND / OR PREVENTION OF PATHOGENIC FUNGAL INFECTIONS AND MAINTAINING MICROBIOMAL COMENSALISM |
| CN112074286A (zh) | 2018-01-23 | 2020-12-11 | 吉拉毒蜥治疗公司 | 肽yy药物制剂、组合物和方法 |
| TW202535916A (zh) | 2018-11-01 | 2025-09-16 | 美商美國禮來大藥廠 | 蛋白質酪胺酸-酪胺酸類似物及其使用方法 |
| IL283182B2 (en) | 2018-11-20 | 2025-10-01 | Tes Pharma S R L | Alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase inhibitors |
| EP4366755A4 (en) * | 2021-07-08 | 2025-09-24 | Gila Therapeutics Inc | COMPOSITIONS AND METHODS FOR ACTIVATING A NEURAL RECEPTOR |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| ATE12348T1 (de) | 1980-11-10 | 1985-04-15 | Gersonde Klaus Prof Dr | Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens. |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| JPS58118008A (ja) | 1982-01-06 | 1983-07-13 | Nec Corp | デ−タ処理装置 |
| EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
| DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| ATE159858T1 (de) | 1983-09-26 | 1997-11-15 | Ehrenfeld Udo | Mittel und erzeugnis für die diagnose und therapie von tumoren sowie zur behandlung von schwächen der zelligen und humoralen immunabwehr |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| CA1257199A (en) | 1986-05-20 | 1989-07-11 | Paul Y. Wang | Preparation containing bioactive macromolecular substance for multi-months release in vivo |
| FI906411A0 (fi) | 1988-06-28 | 1990-12-27 | Jolla Cancer Res Found | Foerhindring av cellfoeroekning med decorin. |
| US5026685A (en) | 1988-07-15 | 1991-06-25 | The Salk Institute For Biological Studies | NPY peptide analogs |
| US5349052A (en) | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| SE9002278L (sv) | 1990-06-28 | 1991-12-29 | Perstorp Ab | Anvaendning av inositoltrisfosfat foer framstaellning av ett laekemedel |
| IT1243390B (it) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
| ATE180510T1 (de) | 1991-11-06 | 1999-06-15 | Garvan Inst Med Res | Humaner neuropeptid y-y1 rezeptor |
| DK39892D0 (da) | 1992-03-25 | 1992-03-25 | Bernard Thorens | Peptid |
| WO1994022467A1 (en) | 1993-03-29 | 1994-10-13 | University Of Cincinnati | Analogs of peptide yy and uses thereof |
| WO1995000162A1 (en) | 1993-06-21 | 1995-01-05 | Enzon, Inc. | Site specific synthesis of conjugated peptides |
| GB9317618D0 (en) | 1993-08-24 | 1993-10-06 | Royal Free Hosp School Med | Polymer modifications |
| US5880131A (en) | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5965566A (en) | 1993-10-20 | 1999-10-12 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5696093A (en) | 1994-10-28 | 1997-12-09 | Crc For Biopharmaceutical Research Pty Limited | Method of treating nasal congestion using neuropeptide Y Y2 agonist peptides |
| US5574010A (en) | 1994-11-14 | 1996-11-12 | The Regents Of The University Of California | Treatment of pancreatic tumors with peptide YY and analogs thereof |
| US5907030A (en) | 1995-01-25 | 1999-05-25 | University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
| US6558708B1 (en) | 1995-05-17 | 2003-05-06 | Cedars-Sinai Medical Center | Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia |
| WO1997027840A1 (en) | 1996-02-02 | 1997-08-07 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
| US5962270A (en) | 1996-02-06 | 1999-10-05 | Bionebraska, Inc. | Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs |
| US6355478B1 (en) | 1996-06-17 | 2002-03-12 | Eli Lilly And Company | Rhesus monkey neuropeptide Y Y2 receptor |
| DE69737479T4 (de) * | 1996-08-30 | 2010-05-06 | Novo Nordisk A/S | Glp-1 derivate |
| UA65549C2 (uk) * | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| CA2277112C (en) * | 1997-01-07 | 2008-08-26 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the reduction of food intake |
| ATE200030T1 (de) | 1997-01-29 | 2001-04-15 | Polymasc Pharmaceuticals Plc | Pegylationsverfahren |
| US6093692A (en) | 1997-09-25 | 2000-07-25 | The University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
| CA2307792C (en) * | 1997-10-31 | 2007-06-26 | Children's Medical Center Corporation | Method for regulating size and growth of vascularized normal tissue |
| EP0920864A1 (en) * | 1997-12-03 | 1999-06-09 | Pfizer Products Inc. | Combination therapy including a specific beta-3 agonist and an anorectic agent |
| FR2774674B1 (fr) | 1998-02-10 | 2000-03-24 | Atochem Elf Sa | Procede de preparation d'une solution aqueuse de peroxyde d'hydrogene directement a partir d'hydrogene et d'oxygene et dispositif permettant sa mise en oeuvre |
| WO1999043707A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | N-terminally modified glp-1 derivatives |
| US6046167A (en) | 1998-03-25 | 2000-04-04 | University Of Cincinnati | Peptide YY analogs |
| FR2777283B1 (fr) | 1998-04-10 | 2000-11-24 | Adir | Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US5993414A (en) | 1998-04-23 | 1999-11-30 | Medtronic, Inc. | Implantable device |
| TWI242000B (en) | 1998-12-10 | 2005-10-21 | Univ Southern California | Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use |
| AU3033500A (en) | 1999-01-15 | 2000-08-01 | Agouron Pharmaceuticals, Inc. | Non-peptide glp-1 agonists |
| US7396809B1 (en) * | 1999-02-10 | 2008-07-08 | Curis, Inc. | Methods and reagents for treating glucose metabolic disorders |
| WO2000059887A1 (en) | 1999-04-02 | 2000-10-12 | Neurogen Corporation | Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics |
| PT1133312E (pt) | 1999-06-21 | 2007-11-30 | Lilly Co Eli | Uso sinergístico de tiazolidinodionas com péptido 1 semelhante ao glucagon e os seus agonistas para tratar diabetes não insulino-dependente |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| US6608098B1 (en) | 1999-08-25 | 2003-08-19 | Banyu Pharmaceutical Co., Ltd. | Isoindole derivatives |
| AU6798000A (en) | 1999-08-26 | 2001-03-19 | Viropharma Incorporated | Compounds, compositions and methods for treating influenza |
| JP2003516322A (ja) | 1999-11-12 | 2003-05-13 | ノボ ノルディスク アクティーゼルスカブ | ベータ細胞変性抑制のためのｇｌｐ−１アゴニストの使用 |
| US6436091B1 (en) | 1999-11-16 | 2002-08-20 | Microsolutions, Inc. | Methods and implantable devices and systems for long term delivery of a pharmaceutical agent |
| CA2396157A1 (en) * | 2000-01-10 | 2001-07-19 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia |
| EP1634605A3 (en) | 2000-03-08 | 2006-10-11 | Novo Nordisk A/S | treatment of dyslipidemia in a patient having type 2 diabetes |
| EP1282436B1 (en) | 2000-05-19 | 2008-06-11 | Amylin Pharmaceuticals, Inc. | Treatment of acute coronary syndrome with glp-1 |
| KR100854851B1 (ko) | 2000-07-06 | 2008-08-27 | 메타베이시스 테라퓨틱스, 인크. | 당뇨병 치료에 유용한 ＦＢＰａｓｅ 억제제와 항당뇨제의조합물 |
| US6420352B1 (en) | 2000-07-19 | 2002-07-16 | W. Roy Knowles | Hair loss prevention |
| US8273713B2 (en) * | 2000-12-14 | 2012-09-25 | Amylin Pharmaceuticals, Llc | Methods of treating obesity using PYY[3-36] |
| WO2002066479A1 (en) | 2001-02-23 | 2002-08-29 | Banyu Pharmaceutical Co.,Ltd. | Novel isoindole derivatives |
| WO2002067918A1 (en) | 2001-02-27 | 2002-09-06 | Banyu Pharmaceutical Co., Ltd. | Novel diallylmethylamine derivative |
-
2003
- 2003-01-10 JP JP2003557592A patent/JP4733922B2/ja not_active Expired - Fee Related
- 2003-01-10 EP EP10186174.8A patent/EP2329839B1/en not_active Expired - Lifetime
- 2003-01-10 CA CA002472882A patent/CA2472882A1/en not_active Abandoned
- 2003-01-10 EP EP03700848A patent/EP1474163A2/en not_active Withdrawn
- 2003-01-10 WO PCT/GB2003/000062 patent/WO2003057235A2/en not_active Ceased
- 2003-01-10 AU AU2003201998A patent/AU2003201998C1/en not_active Ceased
-
2009
- 2009-07-23 AU AU2009203001A patent/AU2009203001B2/en not_active Ceased
- 2009-08-24 JP JP2009193064A patent/JP5226628B2/ja not_active Expired - Fee Related
-
2010
- 2010-12-10 JP JP2010275256A patent/JP2011052018A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005519059A5 (cg-RX-API-DMAC7.html) | ||
| JP2004501162A5 (cg-RX-API-DMAC7.html) | ||
| DK1531791T3 (da) | Forebyggelse og begrænsning af iskæmi | |
| JP2005505579A5 (cg-RX-API-DMAC7.html) | ||
| WO2006029393A8 (en) | Process for preparation of mixtures of polypeptides using purified hydrobromic acid | |
| JP2007001987A5 (cg-RX-API-DMAC7.html) | ||
| EP2022505A3 (en) | GLP-1, exendin-4, peptide analogs and uses thereof | |
| EP1884247A3 (en) | Gastrin compositions and formulations, and methods of use and preparation | |
| DE60313858D1 (de) | Peptidhaltige kosmetische oder pharmazeutische zusammensetzung | |
| JP2004521123A5 (cg-RX-API-DMAC7.html) | ||
| CO5640143A2 (es) | Formulaciones parenterales de un peptido para el tratamiento de lupus eritematoso sistematico | |
| JP2005516996A5 (cg-RX-API-DMAC7.html) | ||
| WO2004009615A3 (en) | Cd40-ligand lacking native-pattern glycosylation | |
| ATE474589T1 (de) | Angiogene peptide und ihre verwendungen | |
| AU2865801A (en) | Therapeutic peptides | |
| WO2001042287A3 (en) | Putative human g-protein coupled receptors | |
| JP2005535281A5 (cg-RX-API-DMAC7.html) | ||
| WO1998025955A3 (en) | Cloned glucagon-like peptide-2 receptors | |
| DE60036676D1 (de) | G-protein-gekoppelter rezeptor-ähnliche proteine | |
| WO2002088183A3 (en) | G-protein coupled receptor | |
| WO2003033536A3 (en) | G-protein coupled receptor | |
| WO2001072842A3 (en) | Human 7-transmembrane proteins and polynucleotides encoding the same | |
| WO2002092624A3 (en) | G-protein coupled receptor | |
| EP1225183A3 (en) | Human G-protein coupled receptor | |
| RU2025116817A (ru) | Новый тройной агонист рецепторов GLP-1/GIP/глюкагонового рецептора и содержащая его фармацевтическая композиция для предупреждения или лечения ожирения |